Clinical trial · Observational
Outcome Analysis of Aspirin in Liver Transplantation
Outcome Analysis of Antiplatelet Therapy With Aspirin in Liver Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the experimental setting inhibition of platelet activation was able to reduce immune-mediated necroinflammatory liver disease and consecutively hepatocellular carcinoma development. Therefore, antiplatelet therapy may not only have a preventive effect on hepatic artery patency but also on tumor recurrence. So far and to the best of our knowledge, no study investigated the effect of antiplatelet therapy on hepatic arterial patency, tumor recurrence and graft survival after primary liver transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Transplant; Complications | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aspirin | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Aspirin and arterial patency
- timeFrame
- 2 years
- description
- We will look, if antiplatelet therapy with Aspirin has a protective effect on arterial patency after primary liver transplantation by looking at postoperative lab values and imaging, if they were perfromed.
Secondary outcomes (3)
- measure
- Aspirin and cellular rejection
- timeFrame
- 2 years
- description
- We will analyze patients with and without postoperative cellular rejection and the intake of Aspirin.
- measure
- Aspirin and tumor recurrence
- timeFrame
- 2 years
- description
- We will look at post transplant tumor recurrence and if the recurrence does correlate with Aspirin intake.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult Liver transplantation(age ≥18 years) * Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD) * Primary liver transplantation, whole graft * Arterial anastomosis: end-to-end, back table reconstruction Exclusion Criteria: * Split liver and living donor liver transplantation * Paediatric liver transplantation (recipient age \<18 years) * Arterial conduits * Multivisceral transplantations * Retransplantations
References
Publications (0)
Data not yet available